Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F, Favalli G; SOCRATES and MITO investigators. Pignata S, et al. Among authors: ballardini m. Oncology. 2006;71(5-6):320-6. doi: 10.1159/000108592. Epub 2007 Sep 18. Oncology. 2006. PMID: 17878745
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Villa A, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Lombardi AV, Sorio R, Mangili G, Priolo D, Magni G, Morabito A. Pignata S, et al. Among authors: ballardini m. BMC Cancer. 2008 Sep 1;8:252. doi: 10.1186/1471-2407-8-252. BMC Cancer. 2008. PMID: 18761742 Free PMC article.
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A. Pignata S, et al. Among authors: ballardini m. Crit Rev Oncol Hematol. 2009 Sep;71(3):233-41. doi: 10.1016/j.critrevonc.2008.12.010. Epub 2009 Jan 28. Crit Rev Oncol Hematol. 2009. PMID: 19179095
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P; After 6 Italian Cooperative Group. Pecorelli S, et al. Among authors: ballardini m. J Clin Oncol. 2009 Oct 1;27(28):4642-8. doi: 10.1200/JCO.2009.21.9691. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704064 Clinical Trial.
Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2).
Gadducci A, Katsaros D, Zola P, Scambia G, Ballardini M, Pasquini E, Fertonani C, Maggi L, Pecorelli S, Conte PF; Members of the After-6 Italian Cooperative Group. Gadducci A, et al. Among authors: ballardini m. Int J Gynecol Cancer. 2009 May;19(4):615-9. doi: 10.1111/IGC.0b013e3181a4476b. Int J Gynecol Cancer. 2009. PMID: 19509559 Clinical Trial.
Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience.
De Giorgi U, Demirer T, Wandt H, Taverna C, Siegert W, Bornhauser M, Kozak T, Papiani G, Ballardini M, Rosti G; Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation. De Giorgi U, et al. Among authors: ballardini m. Ann Oncol. 2005 Jan;16(1):146-51. doi: 10.1093/annonc/mdi017. Ann Oncol. 2005. PMID: 15598952 Free article.
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R; Italian Melanoma Intergroup. Ridolfi L, et al. Among authors: ballardini m. Melanoma Res. 2009 Apr;19(2):100-5. doi: 10.1097/CMR.0b013e328328f7ec. Melanoma Res. 2009. PMID: 19262411 Clinical Trial.
First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party.
Rosti G, De Giorgi U, Wandt H, Lioure B, Leyvraz S, Kolbe K, Papiani G, Ballardini M, Kulekci A, Demirer T; Solid Tumours Working Party. Rosti G, et al. Among authors: ballardini m. Bone Marrow Transplant. 2004 Dec;34(12):1033-7. doi: 10.1038/sj.bmt.1704704. Bone Marrow Transplant. 2004. PMID: 15516940
59 results